Maja Hojnik

1.6k total citations
33 papers, 980 citations indexed

About

Maja Hojnik is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Maja Hojnik has authored 33 papers receiving a total of 980 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Rheumatology, 19 papers in Immunology and 9 papers in Hematology. Recurrent topics in Maja Hojnik's work include Psoriasis: Treatment and Pathogenesis (16 papers), Spondyloarthritis Studies and Treatments (15 papers) and Systemic Lupus Erythematosus Research (13 papers). Maja Hojnik is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (16 papers), Spondyloarthritis Studies and Treatments (15 papers) and Systemic Lupus Erythematosus Research (13 papers). Maja Hojnik collaborates with scholars based in United States, Germany and United Kingdom. Maja Hojnik's co-authors include Yehuda Shoenfeld, Jacob George, Lea Ziporen, Boris Gilburd, Miri Blank, Eiji Matsuura, Yair Levy, Pnina Langevitz, Takao Koike and Joachim Sieper and has published in prestigious journals such as Circulation, The Journal of Immunology and Annals of the Rheumatic Diseases.

In The Last Decade

Maja Hojnik

33 papers receiving 955 citations

Peers

Countries citing papers authored by Maja Hojnik

Since Specialization

Citations

This map shows the geographic impact of Maja Hojnik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maja Hojnik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maja Hojnik more than expected).

Fields of papers citing papers by Maja Hojnik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maja Hojnik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maja Hojnik. The network helps show where Maja Hojnik may publish in the future.

Co-authorship network of co-authors of Maja Hojnik

This figure shows the co-authorship network connecting the top 25 collaborators of Maja Hojnik. A scholar is included among the top collaborators of Maja Hojnik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maja Hojnik. Maja Hojnik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effects of ixekizumab treatment on structural changes in the sacroiliac joint: MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis 2022 ·The Lancet Rheumatology ·Walter P. Maksymowych, Xenofon Baraliakos, R. Lambert, Robert Landewé, David Sandoval, Hilde Carlier, Jeffrey Lisse, Xiaoqi Li, Maja Hojnik, Mikkel Østergaard	15
2	Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double‐Blind Withdrawal Study 2021 ·Arthritis & Rheumatology ·Laura C. Coates, Sreekumar Pillai, Hasan Tahir, Ivo Valter, Vinod Chandran, Hideto Kameda, Masato Okada, Lisa Kerr, (unknown), So Young Park, David H. Adams, Gaia Gallo, Matthew M. Hufford, Maja Hojnik, Philip J. Mease, Arthur Kavanaugh, (unknown)	16
3	Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y) 2021 ·Annals of the Rheumatic Diseases ·Robert Landewé, Lianne S. Gensler, Denis Poddubnyy, Proton Rahman, Maja Hojnik, Xiaoqi Li, Soyi Liu Leage, David H. Adams, Hilde Carlier, Filip Van den Bosch, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	19
4	Characteristics of patients with axial spondyloarthritis by geographic regions: PROOF multicountry observational study baseline results 2021 ·Lara D. Veeken ·Denis Poddubnyy, Joachim Sieper, Servet Akar, Santiago Muñoz‐Fernández, Hildrun Haibel, Maja Hojnik, (unknown), Robert D. Inman	31
5	Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52 2020 ·Annals of the Rheumatic Diseases ·Josef S Smolen, Philip J. Mease, Hasan Tahir, Hendrik Schulze‐Koops, Inmaculada de la Torre, Lingnan Li, Maja Hojnik, Christophe Sapin, Masato Okada, Roberto Caporali, Jordi Gratacós, Philippe Goupille, Soyi Liu Leage, Sreekumar Pillai, Peter Nash	58
6	Low Incidence of Inflammatory Bowel Disease Adverse Events in Adalimumab Clinical Trials Across Nine Different Diseases 2020 ·Arthritis Care & Research ·Dirk Elewaut, Jürgen Braun, J. Anderson, Dilek Arikan, Su Chen, Maja Hojnik, Ann‐Sophie De Craemer, Jeffrey R. Curtis	6
7	Association between clinical specialty setting and disease management in patients with psoriatic arthritis: results from LOOP, a cross‐sectional, multi‐country, observational study 2020 ·Journal of the European Academy of Dermatology and Venereology ·Wolf‐Henning Boehncke, Rudolf Horváth, Ediz Dalkılıç, (unknown), Masato Okada, Maja Hojnik, (unknown), Ennio Lubrano	12
8	A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naive Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks 2019 ·Queensland's institutional digital repository (The University of Queensland) ·Josef S Smolen, Peter Nash, Hasan Tahir, Hendrik Schulze‐Koops, Lingnan Li, Maja Hojnik, (unknown), Soyi Liu-Léage, Sreekumar Pillai, Philip J. Mease	1
9	Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study 2019 ·RMD Open ·Josef S Smolen, Dafna D. Gladman, H. Patrick McNeil, Philip J. Mease, Joachim Sieper, Maja Hojnik, Pascal Nurwakagari, John Weinman	43
10	Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the ImPact ofResidual Inflammation Detected via Imaging TEchniques,Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab inClinical Remission Rheumatoid ArThritis (RA) patients (PREDICTRA) 2018 ·BMJ Open ·Paul Emery, Gerd R Burmester, Esperanza Naredo, Yijie Zhou, Maja Hojnik, Philip G. Conaghan	6
11	Impact of adalimumab on clinical outcomes, healthcare resource utilization, and sick leave in patients with ankylosing spondylitis: an observational study from five Central and Eastern European countries 2018 ·Drugs in Context ·Daniela Opriș-Belinski, Ш. Ф. Эрдес, Simeon Grazio, Ladislav Šenolt, Maja Hojnik, Orsolya Nagy, (unknown), Sándor Szántó	7
12	Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial 2018 ·Arthritis Research & Therapy ·Désirée van der Heijde, Joachim Sieper, Walter P. Maksymowych, R. Lambert, Su Chen, Maja Hojnik, J. Anderson, Aileen L. Pangan	30
13	Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial 2017 ·RMD Open ·Philip J. Mease, Arthur Kavanaugh, Laura C. Coates, Iain B. McInnes, Maja Hojnik, Ying Zhang, J. Anderson, (unknown), Dafna D. Gladman	24
14	Incidence of Inflammatory Bowel Disease Events in Adalimumab Clinical Trials Across Indications 2017 ·SKIN The Journal of Cutaneous Medicine ·Jeffrey R. Curtis, Dirk Elewaut, Su Chen, Maja Hojnik, (unknown), J. Anderson	1
15	Musculoskeletal ultrasonography in routine rheumatology practice: data from Central and Eastern European countries 2016 ·Rheumatology International ·Péter Mandl, Asta Baranauskaitė, Nemanja Damjanov, Maja Hojnik, Réka Kurucz, Orsolya Nagy, Petr Němec, Dora Niedermayer, (unknown), (unknown), (unknown), Simona Rednic, Violeta Vlad, (unknown), P Bálint	8
16	Effectiveness of adalimumab in the treatment of scalp and nail affection in patients with moderate to severe plaque psoriasis in routine clinical practice 2016 ·Acta Dermatovenerologica Alpina Pannonica et Adriatica ·(unknown), (unknown), Andrea Szegedi, Lev Pavlovsky, (unknown), Külli Kingo, Jovan Miljković, J. Péč, (unknown), Maja Hojnik	19
17	Anti-β2-glycoprotein I antibodies of IgM class are linked to thrombotic disorders in young women without autoimmune disease 2007 ·Immunobiology ·Barbara Salobir, Mišo Šabović, Maja Hojnik, Saša Čučnik, Tanja Kveder	5
18	The association of HLA-DR/DQ coding and QBP promoter allelic polymorphism with antiphospholipid antibody response in SLE 2002 ·Arthritis Research ·D Logar, Blanka Vidan‐Jeras, Aleš Ambrožič, Vita Dolžan, Maja Hojnik, Borut Božič, (unknown)	1
19	Target Recognition of β2-Glycoprotein I (β2GPI)-Dependent Anticardiolipin Antibodies: Evidence for Involvement of the Fourth Domain of β2GPI in Antibody Binding 1998 ·The Journal of Immunology ·Jacob George, Boris Gilburd, Maja Hojnik, Yair Levy, Pnina Langevitz, Eiji Matsuura, Takao Koike, Yehuda Shoenfeld	49
20	Anticardiolipin Antibodies in Infections are Heterogenous in Their Dependency on β 2-Glycoprotein I: Analysis of Anticardiolipin Antibodies in Leprosy 1994 ·Lupus ·Maja Hojnik, Boris Gilburd, Lea Ziporen, Miri Blank, Yaron Tomer, Morton Scheinberg, Anǵela Tincani, Blaž Rozman, Yehuda Shoenfeld	61

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact